{"entity":{"id":"idea-tr2-antagonism-surveillance","kind":"idea","name":"Watch routine care for drug combinations that quietly make cancer treatment worse","aka":[],"tldr":"Some everyday medicines, such as antibiotics or steroids, seem to blunt immunotherapy. Automatically scanning health records for such harmful pairs would catch them years earlier.","summary":"Antibiotics, proton-pump inhibitors and corticosteroids are associated with worse outcomes on checkpoint inhibitors in retrospective series, yet these signals took years to surface. A pharmacovigilance-style system that continuously screens clinico-genomic databases for concomitant medications associated with reduced efficacy (not just toxicity) would generate hypotheses for confirmation and, where confirmed, guideline warnings.","asOf":"2026-09-08","links":[{"label":"Bottleneck evidence (Too many combinations to test): Palmer & Sorger, Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy (Cell 2017)","url":"https://doi.org/10.1016/j.cell.2017.11.009"}],"tags":[],"related":["tempus"],"cancers":[],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["pembrolizumab","nivolumab"],"companies":[],"institutions":[],"pathways":[],"terms":["real-world-evidence"],"trials":[],"people":[],"bottlenecks":["b-combination-space","b-real-world-evidence"],"keyPapers":["paper-palmer-cell"],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"Systematic surveillance will identify at least three previously unrecognised efficacy-reducing co-medications for immunotherapy or targeted therapy within two years, at least one of which is confirmed in a randomised or well-controlled study.","rationale":"Adverse-event pharmacovigilance is mature; efficacy pharmacovigilance is not, even though negative interactions on survival matter more than most side-effects.","test":"Run signal detection across a large clinico-genomic database for patients on PD-1 inhibitors; validate top signals in an independent registry; publish a ranked list.","maturity":"early-clinical","actor":"data","cost":"small","horizonYears":2},"route":"/ideas/idea-tr2-antagonism-surveillance/","neighbours":{"company":[{"id":"tempus","kind":"company","name":"Tempus AI","route":"/companies/tempus/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"term":[{"id":"real-world-evidence","kind":"term","name":"Real-world evidence","route":"/terms/real-world-evidence/"}],"bottleneck":[{"id":"b-combination-space","kind":"bottleneck","name":"Too many combinations to test","route":"/bottlenecks/b-combination-space/"},{"id":"b-real-world-evidence","kind":"bottleneck","name":"Weak real-world evidence and registries","route":"/bottlenecks/b-real-world-evidence/"}],"paper":[{"id":"paper-palmer-cell","kind":"paper","name":"Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy","route":"/key-papers/paper-palmer-cell/"}]}}